Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
Open Access
- 11 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 52 (11), 1017-1027
- https://doi.org/10.1007/s40262-013-0085-2
Abstract
Sifalimumab is a fully human immunoglobulin G1κ monoclonal antibody that binds to and neutralizes a majority of the subtypes of human interferon-α. Sifalimumab is being evaluated as a treatment for systemic lupus erythematosus (SLE). The primary objectives of this analysis were (a) to develop a population pharmacokinetic model for sifalimumab in SLE; (b) to identify and quantitate the impact of patient/disease characteristics on pharmacokinetic variability; and (c) to evaluate fixed versus body weight (WT)-based dosing regimens.Keywords
This publication has 46 references indexed in Scilit:
- Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation StudyArthritis & Rheumatism, 2013
- Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone MetaboliteClinical Pharmacokinetics, 2010
- An open‐label, single‐dose bioavailability study of the pharmacokinetics of CAT‐354 after subcutaneous and intravenous administration in healthy malesBritish Journal of Clinical Pharmacology, 2010
- A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthmaBMC Pulmonary Medicine, 2010
- Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and NeckThe Journal of Clinical Pharmacology, 2008
- Interferons as pathogenic effectors in autoimmunityImmunological Reviews, 2005
- Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosusLupus, 2001
- A Size Standard for PharmacokineticsClinical Pharmacokinetics, 1996
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1983